First let me point out that at the bottom of the article it states “Commenting is limited to medical professionals.” Those medical professionals have to log in as well. So we, the public the parents, and family members with injured children have no say at all.
This comes after 228 deaths and almost 40,000 adverse reactions have been reported to VAERS. Remember only 1 to 10% of the vaccine injured are reporting so start doing the math.
Even though the review is not questioning whether the benefits are outweighing the risks…the fact that the EMA is looking at the safety profile is huge. And is due to the activism in this country and in the UK, India and Europe.
You can run but you cannot hide… and they are running out of places to hide.
Safety Profile of HPV Vaccines Under Review in Europe
The European Medicines Agency has started a review of human papillomavirus (HPV) vaccines “to further clarify aspects of their safety profile,” although the agency also points out that this review “does not question that the benefits of HPV vaccines outweigh their risks.”
The agency also notes that while the review is being carried out, no change in the use of these products is recommended.
HPV vaccines are now routinely given in immunization programs in many countries, and worldwide are estimated to have been given to more than 72 million people. They are expected to protect against cervical cancer as well as other cancers and conditions that are associated with the virus, including anal cancer and genital warts.
The review was initiated at the request of Denmark and will look specifically at the data for two conditions that have been reported, rarely, with the vaccines:
- complex regional pain syndrome (CRPS), a chronic pain condition affecting the limbs, and
- postural orthostatic tachycardia syndrome (POTS), a condition in which the heart rate increases abnormally after sitting or standing up, causing symptoms such as dizziness and fainting, as well as headache, chest pain, and weakness.
Reports of these two conditions occurring in young women who have received an HPV vaccine have been previously considered during routine safety monitoring by the agency’s Pharmacovigilance Risk Assessment Committee, but at that time, a causal link between them and the vaccines was not established.
The agency points out that “both conditions can occur in non-vaccinated individuals and it is considered important to further review if the number of cases reported with HPV vaccine is greater than would be expected.”
The review will consider any research that could help clarify the frequency of the two conditions after vaccination or identify any causal link, and on completion of the review, it will decide whether changes to product information are needed.
A recent report on these two syndromes, CRPS and POTS, occurring after HPV vaccination was published online May 20 and in the July issue of Clinical Rheumatology.
“The symptoms more often reported are chronic pain with paresthesias, headaches, fatigue, and orthostatic intolerance,” writes Manuel Martínez-Lavín, MD, from the Rheumatology Department, Instituto Nacional de Cardiología Ignacio Chávez in Mexico City, Mexico. “Adverse reactions appear to be more frequent after HPV vaccination when compared to other type[s] of immunizations. Different isolated cases and small series have described the development of [CRPS], [POTS], and fibromyalgia after HPV vaccination.”
These are illnesses often difficult to diagnose, and they have several overlapping clinical features, he writes. “Sympathetic nervous system dysfunction seems to play a major role in the pathogenesis of these syndromes. Also, small fiber neuropathy has been recently recognized in CRPS, POTS, and fibromyalgia.”
Please read an excellent expose on this press release here.